NEW YORK (GenomeWeb News) - Clarient has acquired an exclusive license to Health Discovery Corporation’s prostate cancer marker and plans to develop and commercialize a test based on the marker, HDC said today.
 
Under the agreement, HDC will receive a 30 percent royalty payment for all prostate cancer tests Clarient performs for third parties using the technology.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.